SSRI augmentation of antipsychotic alters expression of GABA A receptor and related genes in PMC of schizophrenia patients

International Journal of Neuropsychopharmacology

Volumn 14, Issue 5, 2011, Pages 573-584

  Silver, Henry ^a,d   Susser, Ehud ^a   Danovich, Lena ^a   Bilker, Warren ^c   Youdim, Moussa ^b   Goldin, Vladimir ^a   Weinreb, Orly ^a,b  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Mobile Post Hefer 38814   (Israel)

Author keywords

antipsychotics; GABA A receptor; peripheral mononuclear cells; Schizophrenia; SSRI antidepressant

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR BETA3; BRAIN DERIVED NEUROTROPHIC FACTOR; FLUVOXAMINE; MESSENGER RNA; NEUROLEPTIC AGENT; OLANZAPINE; PHARMACOLOGICAL BIOMARKER; PROTEIN KINASE C BETA; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; ZIPRASIDONE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INVOLUNTARY MOVEMENT; MALE; NEGATIVE SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYPHARMACY; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; SCHIZOPHRENIA; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; PROTEIN KINASE C; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, GABA-A; RNA, MESSENGER; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS;

EID: 79956015810     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710001471     Document Type: Article

References (58)

1. Alam S, Laughton DL, Walding A, Wolstenholme AJ (2006). Human peripheral blood mononuclear cells express GABA-A receptor subunits. Molecular Immunology 43, 1432-1442. (Pubitemid 43356383)
2. Angelucci F, Brene S, Mathe AA (2005). BDNF in schizophrenia, depression and corresponding animal models. Molecular Psychiatry 10, 345-352.
3. Arnsten AF (2009). Stress signaling pathways that impair prefrontal cortex structure and function. Nature Reviews Neuroscience 10, 410-422.
4. Arranz B, Rosel P, Sarro S, Ramirez N, et al. (2003). Altered platelet serotonin 5-HT2A receptor density but not second messenger inositol trisphosphate levels in drug-free schizophrenic patients. Psychiatry Research 118, 165-174. (Pubitemid 36694430)
5. Arranz M, Collier D, Sodhi M, Ball D, et al. (1995). Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346, 281-282.
6. Benes FM, Vincent SL, Marie A, Khan Y (1996). Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75, 1021-1031. (Pubitemid 26377090)
7. Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, et al. (2004). Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. American Journal of Psychiatry 161, 368-370. (Pubitemid 38419291)
8. Bhattacharyya S, Puri S, Miledi R, Panicker MM (2002). Internalization and recycling of 5-HT2A receptors activated by serotonin and protein kinase C-mediated mechanisms. Proceedings of the National Academy of Sciences Online (USA) 99, 14470-14475. (Pubitemid 35257695)
9. Birnbaum SG, Yuan PX, Wang M, Vijayraghavan S, et al. (2004). Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science 306, 882-884. (Pubitemid 39446999)
10. Bloch MH, Landeros-Weisenberger A, KelmendiB, Coric V, et al. (2006). A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry 11, 622-632. (Pubitemid 43989810)
11. Bobo WV, Shelton RC (2009). Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. Expert Opinion on Pharmacotherapy 10, 2145-2159.
12. Brandon NJ, Delmas P, Kittler JT, McDonald BJ, et al. (2000). GABAA receptor phosphorylation and functional modulation in cortical neurons by a protein kinase C-dependent pathway. Journal of Biological Chemistry 275, 38856-38862. (Pubitemid 32009223)
13. Brandon NJ, Uren JM, Kittler JT, Wang H, et al. (1999). Subunit-specific association of protein kinase C and the receptor for activated C kinase with GABA type A receptors. Journal of Neuroscience 19, 9228-9934.
14. Carlsson A, Waters N, Holm-Waters S, Tedroff J, et al. (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annual Review of Pharmacology and Toxicology 41, 237-260. (Pubitemid 32385889)
15. Chertkow Y, Weinreb O, Youdim MB, Silver H (2006). The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex. International Journal of Neuropsychopharmacology 9, 287-296. (Pubitemid 43780496)
16. Chertkow Y, Weinreb O, Youdim MB, Silver H (2007). Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 31, 1356-1362. (Pubitemid 47302546)
17. Coba MP, Pocklington AJ, Collins MO, Kopanitsa MV, et al. (2009). Neurotransmitters drive combinatorial multistate postsynaptic density networks. Science Signaling 2, ra19.
18. Danovich L, Weinreb O, Youdim MB, Silver H (2010). The involvement of GABAA receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment. International Journal of Neuropsychopharmacology 25, 1-13.
19. Dean B, Hussain T, Hayes W, Scarr E, et al. (1999). Changes in serotonin2A and GABA(A) receptors in schizophrenia : studies on the human dorsolateral prefrontal cortex. Journal of Neurochemistry 72, 1593-1599. (Pubitemid 29140833)
20. East SZ, Burnet PW, Kerwin RW, Harrison PJ (2002). An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia. Schizophrenia Research 57, 15-26.
21. Falkai P, Wobrock T, Lieberman J, Glenthoj B, et al. (2006). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World Journal of Biological Psychiatry 7, 5-40. (Pubitemid 43878525)
22. Feng J, Cai X, Zhao J, Yan Z (2001). Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. Journal of Neuroscience 21, 6502-6511. (Pubitemid 32781094)
23. Gladkevich A, Kauffman HF, Korf J (2004). Lymphocyts as a neural probe: potential for studying psychiatric disorders. Progress in Neuro- Psychopharmacology and Biological Psychiatry 28, 559-576. (Pubitemid 38490769)
24. Goren MZ, Kucukibrahimoglu E, Berkman K, Terzioglu B (2007). Fluoxetine partly exerts its actions through GABA: a neurochemical evidence. Neurochemical Research 32, 1559-1565. (Pubitemid 47094418)
25. Govitrapong P, Chagkutip J, Turakitwanakan W, Srikiatkhachorn A (2000). Platelet 5-HT(2A) receptors in schizophrenic patients with and without neuroleptic treatment. Psychiatry Research 96, 41-50.
26. Hiemke C, Peled A, Jabarin M, Hadjez J, et al. (2002). Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. Journal of Clinical Psychopharmacology 22, 502-506.
27. Jindal RD, Pillai AK, Mahadik SP, Eklund K, et al. (2010). Decreased BDNF in patients with antipsychotic nä?ve first episode schizophrenia. Schizophrenia Research 119, 47-51.
28. Karege F, Bondolfi G, GervasoniN, Schwald M, et al. (2005). Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biological Psychiatry 57, 1068-1072. (Pubitemid 40613035)
29. Küçükibrahimoglu E, Saygin MZ, Calişkan M, Kaplan OK, et al. (2009). The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. European Journal of Clinical Pharmacology 65, 571-577.
30. Lewis DA, Hashimoto T, Volk DW (2005). Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience 6, 312-324. (Pubitemid 40469985)
31. Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, et al. (2008). Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacological Reviews 60, 358-403.
32. Liew CC, Ma J, Tang HC, Zheng R, et al. (2006). The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. Journal of Laboratory and Clinical Medicine 147, 126-132. (Pubitemid 43288168)
33. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27, 1159-1172. (Pubitemid 37464960)
34. Moresco RM, Colombo C, Fazio F, Bonfanti A, et al. (2000). Smeraldi E. Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study. Neuroimage 12, 452-465.
35. Narita N, Hashimoto K, Tomitaka S, Minabe Y (1996). Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. European Journal of Pharmacology 307, 117-119. (Pubitemid 26226293)
36. Padin JF, Rodriguez MA, Dominguez E, Dopeso-Reyes IG, et al. (2006). Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells. Neuropharmacology 51, 923-932. (Pubitemid 44376403)
37. Piccinni A, Marazziti D, Catena M, Domenici L, et al. (2008). Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. Journal of Affective Disorders 105, 279-283. (Pubitemid 350245688)
38. Rasmussen H, Erritzoe D, Andersen R, Ebdrup BH, et al. (2010). Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Archives of General Psychiatry 67, 9-16.
39. Rummel C, Kissling W, Leucht S (2005). Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophrenia Research 80, 85-97. (Pubitemid 41587466)
40. Sanacora G, Mason GF, Rothman DL, Krystal JH (2002). Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. American Journal of Psychiatry 159, 663-665. (Pubitemid 34274953)
41. Sen S, Duman R, Sanacora G (2008). Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biological Psychiatry 64, 527-532.
42. Shelton RC, Sanders-Bush E, Manier DH, Lewis DA (2009). Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 158, 1406-1415.
43. ShimizuE, HashimotoK, Okamura N, Koike K, et al. (2003). Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biological Psychiatry 54, 70-75. (Pubitemid 36776725)
44. Silver H (2003). Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. International Clinical Psychopharmacology 18, 305-313. (Pubitemid 38183483)
45. Silver H, Aharon N, Kaplan A (2003a). Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms. Schizophrenia Bulletin 29, 541-546. (Pubitemid 37339388)
46. Silver H, Barash I, Aharon N, Kaplan A, et al. (2000). Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. International Clinical Psychopharmacology 15, 257-226.
47. Silver H, Chertkow Y, Weinreb O, Danovich L, et al. (2009). Multifunctional pharmacotherapy:Whatcanwelearn from study of SSRI augmentation of antipsychotics in negative symptom schizophrenia? Neurotherapeutics 6, 86-93.
48. Silver H, Feldman P, Bilker W, Gur RC (2003b). Working memory deficit as a core neuropsychological dysfunction in schizophrenia. American Journal of Psychiatry 160, 1809-1816. (Pubitemid 41103315)
49. Silver H, Kushnir M, Kaplan A (1996). Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biological Psychiatry 40, 671-674. (Pubitemid 26356403)
50. Silver H, Nassar A (1992). Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo controlled study. Biological Psychiatry 31, 698-704.
51. Silver H, Nassar A, Aharon N, Kaplan A (2003c). The onset and time course of response of negative symptoms to add-on fluvoxamine treatment. International Clinical Psychopharmacology 18, 87-92. (Pubitemid 36343977)
52. Silver H, Shmugliakov N (1998). Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double blind study. Journal of Clinical Psychopharmacology 8, 208-211. (Pubitemid 28266886)
53. Song M, Messing RO (2005). Protein kinase C regulation of GABAA receptors. Cellular and Molecular Life Sciences 62, 119-127. (Pubitemid 40193037)
54. Wang G, Hu C, Jiang T, Luo J, et al. (2010). Overexpression of serotonin receptor and transporter mRNA in blood leukocytes of antipsychotic-free and antipsychotic-naive schizophrenic patients: Gender differences. Schizophrenia Research 121, 160-171.
55. Weinberger DR, Berman KF (1988). Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophrenia Bulletin 14, 157-168.
56. Yamamoto H, Gurney ME (1990). Human platelets contain brain-derived neurotrophic factor. Journal of Neuroscience 10, 3469-3478.
57. Yoon JH, Maddock RJ, Rokem A, Silver MA, et al. (2010). GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. Journal of Neuroscience 30, 3777-3781.
58. Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, et al. (2010). Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 34, 308-312.